Xarelto
is an anticoagulant (blood thinner) which blocks the activity of
specific substances that are responsible for blood clotting. Although
blood clotting is a natural process that helps in healing, the clots can
also be form abnormally, break away into the blood stream and obstruct
the flow of blood into body organs.
Manufactured
by Bayer and was released in the U.S. in 2011 by Janssen
Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, Xarelto
was designed to prevent or treat a type of blood clot called deep vein thrombosis (DVT) or pulmonary embolism
(blood clots in the lungs, brain or heart). It is generally prescribed
for patients undergoing certain types of surgeries, such as hip or knee
replacement.
However, there have been complications reported by the patients after taking the drug. They claimed for xarelto legal compensation for all the pain and suffering.
Initially,
Xarelto was marketed as a superior anticoagulant to other existing
blood thinners, like warfarin. But what made it so popular is the most
significant difference between the other drugs that it did not require
regular blood monitoring, dietary restrictions, or frequent dose
adjustments.
Xarelto Side Effects
But
as mentioned, this popular drug was soon linked with various
complications. Inherent to other anticoagulants, Xarelto also puts
patients at risk of hemorrhaging and other internal bleeding chances.
What made it dangerous is there's no way to stop severe bleeding events
caused by Xarelto. Additionally, doctors find it more difficult to
detect internal bleeding in patients taking this drug as there's no
regular blood monitoring tests required with it.
The following health effects have been highlighted by the patients in xarelto legal compensation.
- Intracranial hemorrhages
- Abdominal bleeding
- Retinal bleeding
- Infection
- Wound complications
- Epidural hemorrhage
- Adrenal bleeding
- Excessive blood loss
- Stroke
- Death
FDA Issues Xarelto Warnings
The
U.S. Food and Drug Administration (FDA) in June 2013 sent a letter to
Bayer, Janssen, and Johnson & Johnson, warning that the drug's
advertising was misleading and downplayed the possible fatal side
effects. The FDA also claimed how the branding and advertisements for
Xarelto failed to sufficiently draw attention to the potential effects
of the drug and claims of its effectiveness appeared to be disengaged
from its risks.
Moreover,
the FDA cited inaccuracies in claims made by Xarelto’s manufacturers
that it does not require dosage adjustments, but in actuality the
product’s information sections have contradictory instructions on
warnings and precautions as well as dosage and administration. The FDA
issued a black box warning for Xarelto in August 2013 for its
insufficient warning. The victims of the drug thus gained more courage
to speak up for the xarelto legal compensation.
The
warning from the agency highlighted that patients who discontinued
Xarelto usage prematurely were at a higher risk for developing blood
clots, DPV, and even might risk themselves for spinal or epidural
hematoma. In 2014, the FDA required new language be included in the
safety information and warning for the drug.
Absence
of a Xarelto antidote to treat excessive bleeding has been the main
health concern. The patients are left at the risk of forming blood clots
if they prematurely stop taking the drug.
Patients filing for xarelto legal compensation claim:
- It poses an unnecessary risk of injury through excessive bleeding
- Lack of an antidote to stop excessive bleeding is an inherent design defect
Janssen and Bayer knew about the risks and intentionally concealed evidence
Comments
Post a Comment